FTISADTSK (acetate)

FTISADTSK acetate is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) [1].

Product Specifications

UNSPSC

12352209

Target

Drug Metabolite

Type

Peptides

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ftisadtsk-acetate.html

Purity

99.66

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)[C@H]([C@@H](C)CC)NC([C@H]([C@H](O)C)NC([C@@H](N)CC1=CC=CC=C1)=O)=O.CC(O)=O

Molecular Formula

C44H72N10O18

Molecular Weight

1029.10

References & Citations

[1]Bults P, et al. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem. 2016;88 (3) :1871-1877.